Literature DB >> 29453204

Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes.

Eiichiro Satake1,2, Marcus G Pezzolesi3, Zaipul I Md Dom1,2, Adam M Smiles1, Monika A Niewczas1,2, Andrzej S Krolewski4,2.   

Abstract

We investigated plasma microRNA (miRNA) profiles associated with variation of hyperglycemia, measured as hemoglobin A1c (HbA1c), in two panels of patients with type 1 diabetes (T1D). Using the HTG Molecular Diagnostics EdgeSeq platform, 2,083 miRNAs were measured in plasma from 71 patients included in a screening panel. Quantitative real-time PCR was used to measure the candidate miRNAs in plasma from 95 patients included in an independent replication panel. We found 10 miRNAs replicated in both panels and 4 with high statistical significance. The strongest positive correlations with HbA1c were found with miR-125b-5p (rs = 0.40, P = 6.0 × 10-5) and miR-365a-3p (rs = 0.35, P = 5.9 × 10-4). The strongest negative correlations were found with miR-5190 (rs = -0.30, P = 0.003) and miR-770-5p (rs = -0.27, P = 0.008). Pathway analysis revealed that 50 Kyoto Encyclopedia of Genes and Genomes pathways were significantly enriched by genes targeted by these four miRNAs. The axon guidance signaling pathway was enriched (P < 1 × 10-7) by genes targeted by all four miRNAs. In addition, three other pathways (Rap1 signaling, focal adhesion, and neurotrophin signaling) were also significantly enriched but with genes targeted by only by three of the identified miRNAs. In conclusion, our study identified four circulating miRNAs that were influenced by variation in hyperglycemia. Dysregulation of these miRNAs, which are associated with hyperglycemia in patients with T1D, may contribute to the development of diabetes complications. However, there are multitudes of possible mechanisms/pathways through which dysregulation of these miRNAs may impact risk of diabetes complications.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29453204      PMCID: PMC5910001          DOI: 10.2337/db17-1207

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  47 in total

Review 1.  Paxillin and focal adhesion signalling.

Authors:  C E Turner
Journal:  Nat Cell Biol       Date:  2000-12       Impact factor: 28.824

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

3.  Risk for ESRD in type 1 diabetes remains high despite renoprotection.

Authors:  Elizabeth T Rosolowsky; Jan Skupien; Adam M Smiles; Monika Niewczas; Bijan Roshan; Robert Stanton; John H Eckfeldt; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2011-02-25       Impact factor: 10.121

4.  Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study.

Authors:  Lei Kong; Junjie Zhu; Wenxia Han; Xiuyun Jiang; Min Xu; Yue Zhao; Qiongzhu Dong; Zengfen Pang; Qingbo Guan; Ling Gao; Jiajun Zhao; Lei Zhao
Journal:  Acta Diabetol       Date:  2010-09-21       Impact factor: 4.280

5.  Profiling of circulating microRNAs in children with recent onset of type 1 diabetes.

Authors:  Suheda Erener; Ashish Marwaha; Rusung Tan; Constadina Panagiotopoulos; Timothy J Kieffer
Journal:  JCI Insight       Date:  2017-02-23

6.  Conserved MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K.

Authors:  Seogang Hyun; Jung Hyun Lee; Hua Jin; JinWu Nam; Bumjin Namkoong; Gina Lee; Jongkyeong Chung; V Narry Kim
Journal:  Cell       Date:  2009-12-11       Impact factor: 41.582

7.  miR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker development.

Authors:  Mathieu Latreille; Karolin Herrmanns; Neil Renwick; Thomas Tuschl; Maciej T Malecki; Mark I McCarthy; Katharine R Owen; Thomas Rülicke; Markus Stoffel
Journal:  J Mol Med (Berl)       Date:  2015-05-28       Impact factor: 4.599

8.  Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study.

Authors:  Attila A Seyhan; Yury O Nunez Lopez; Hui Xie; Fanchao Yi; Clayton Mathews; Magdalena Pasarica; Richard E Pratley
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

9.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

10.  Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.

Authors:  Andrzej S Krolewski; Monika A Niewczas; Jan Skupien; Tomhito Gohda; Adam Smiles; Jon H Eckfeldt; Alessandro Doria; James H Warram
Journal:  Diabetes Care       Date:  2013-08-12       Impact factor: 19.112

View more
  30 in total

Review 1.  Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

Review 2.  The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.

Authors:  Alicia Jenkins; Andrzej Januszewski; David O'Neal
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

Review 3.  MicroRNA and Diabetic Bone Disease.

Authors:  Souad Daamouch; Lejla Emini; Martina Rauner; Lorenz C Hofbauer
Journal:  Curr Osteoporos Rep       Date:  2022-06-08       Impact factor: 5.163

Review 4.  Epigenetics Variation and Pathogenesis in Diabetes.

Authors:  Haichen Zhang; Toni I Pollin
Journal:  Curr Diab Rep       Date:  2018-10-02       Impact factor: 4.810

5.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

6.  Increased Expression of Circulating microRNA 101-3p in Type 1 Diabetes Patients: New Insights Into miRNA-Regulated Pathophysiological Pathways for Type 1 Diabetes.

Authors:  Aritania S Santos; Edecio Cunha Neto; Rosa T Fukui; Ludmila R P Ferreira; Maria Elizabeth R Silva
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

7.  mir-124-5p Regulates Phagocytosis of Human Macrophages by Targeting the Actin Cytoskeleton via the ARP2/3 Complex.

Authors:  Estefania Herdoiza Padilla; Peter Crauwels; Tim Bergner; Nicole Wiederspohn; Sabrina Förstner; Rebecca Rinas; Anna Ruf; Michael Kleemann; René Handrick; Jan Tuckermann; Kerstin Otte; Paul Walther; Christian U Riedel
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

8.  Transcriptomic studies revealed pathophysiological impact of COVID-19 to predominant health conditions.

Authors:  Zulkar Nain; Shital K Barman; Md Moinuddin Sheam; Shifath Bin Syed; Abdus Samad; Julian M W Quinn; Mohammad Minnatul Karim; Mahbubul Kabir Himel; Rajib Kanti Roy; Mohammad Ali Moni; Sudhangshu Kumar Biswas
Journal:  Brief Bioinform       Date:  2021-06-02       Impact factor: 11.622

Review 9.  Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease.

Authors:  Mitsuo Kato
Journal:  Kidney Res Clin Pract       Date:  2018-09-30

10.  Urinary miRNA-27b-3p and miRNA-1228-3p correlate with the progression of Kidney Fibrosis in Diabetic Nephropathy.

Authors:  Francesca Conserva; Mariagrazia Barozzino; Francesco Pesce; Chiara Divella; Annarita Oranger; Massimo Papale; Fabio Sallustio; Simona Simone; Luigi Laviola; Francesco Giorgino; Anna Gallone; Paola Pontrelli; Loreto Gesualdo
Journal:  Sci Rep       Date:  2019-08-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.